MX2014005838A - Morfolinilbenzotriazinas para el uso en la terapia de cancer. - Google Patents
Morfolinilbenzotriazinas para el uso en la terapia de cancer.Info
- Publication number
- MX2014005838A MX2014005838A MX2014005838A MX2014005838A MX2014005838A MX 2014005838 A MX2014005838 A MX 2014005838A MX 2014005838 A MX2014005838 A MX 2014005838A MX 2014005838 A MX2014005838 A MX 2014005838A MX 2014005838 A MX2014005838 A MX 2014005838A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- formula
- benzotriazine
- morpholinyl
- cancer therapy
- Prior art date
Links
- JHIMBAPIOFMFBP-UHFFFAOYSA-N 4-(1,2,3-benzotriazin-4-yl)morpholine Chemical compound C1COCCN1C1=NN=NC2=CC=CC=C12 JHIMBAPIOFMFBP-UHFFFAOYSA-N 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 102100030011 Endoribonuclease Human genes 0.000 abstract 1
- 101710199605 Endoribonuclease Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005865 ionizing radiation Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 230000001235 sensitizing effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011118830A DE102011118830A1 (de) | 2011-11-18 | 2011-11-18 | Morpholinylbenzotriazine |
| PCT/EP2012/004542 WO2013072015A1 (de) | 2011-11-18 | 2012-10-30 | Morpholinylbenzotriazine zur anwendung in der krebstherapie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014005838A true MX2014005838A (es) | 2014-07-30 |
Family
ID=47143824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014005838A MX2014005838A (es) | 2011-11-18 | 2012-10-30 | Morfolinilbenzotriazinas para el uso en la terapia de cancer. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9187469B2 (enExample) |
| EP (1) | EP2780332B1 (enExample) |
| JP (1) | JP6096792B2 (enExample) |
| KR (1) | KR20140097391A (enExample) |
| CN (1) | CN103930408B (enExample) |
| AU (1) | AU2012339196B2 (enExample) |
| BR (1) | BR112014011805A2 (enExample) |
| CA (1) | CA2856103C (enExample) |
| DE (1) | DE102011118830A1 (enExample) |
| DK (1) | DK2780332T3 (enExample) |
| EA (1) | EA201400595A1 (enExample) |
| ES (1) | ES2572605T3 (enExample) |
| HK (1) | HK1199875A1 (enExample) |
| HR (1) | HRP20160495T1 (enExample) |
| HU (1) | HUE027577T2 (enExample) |
| IL (1) | IL232577A (enExample) |
| IN (1) | IN2014KN01287A (enExample) |
| MX (1) | MX2014005838A (enExample) |
| PL (1) | PL2780332T3 (enExample) |
| RS (1) | RS54768B1 (enExample) |
| SG (1) | SG11201402206YA (enExample) |
| SI (1) | SI2780332T1 (enExample) |
| WO (1) | WO2013072015A1 (enExample) |
| ZA (1) | ZA201404438B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS58043B1 (sr) | 2012-04-24 | 2019-02-28 | Vertex Pharma | Inhibitori dna-pk |
| EP3985003B1 (en) | 2013-03-12 | 2023-08-09 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| DE102013008118A1 (de) | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| PE20161022A1 (es) | 2013-10-17 | 2016-11-12 | Vertex Pharma | Cocristales de (s)-n-metil-8-(1-((2'-metil-[4,5´-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida y sus derivados deuterados como inhibidores de proteinas quinasa dependientes de adn |
| CA3038657A1 (en) | 2016-09-27 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors |
| CN107793373B (zh) * | 2017-10-31 | 2019-09-17 | 广西师范大学 | 2-取代苯并三嗪酮衍生物及其制备方法 |
| AU2019209292B2 (en) | 2018-01-17 | 2023-10-05 | Vertex Pharmaceuticals Incorporated | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency |
| IL276080B2 (en) | 2018-01-17 | 2023-10-01 | Vertex Pharma | Dna-pk inhibitor compounds, compositions comprising same and uses thereof |
| US12121524B2 (en) | 2018-01-17 | 2024-10-22 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
| IL291996B1 (en) | 2019-11-01 | 2025-09-01 | Syngenta Crop Protection Ag | Molten bicyclic heteroaromatic compounds active as pesticides |
| JP2024527287A (ja) | 2021-06-24 | 2024-07-24 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物剤としての２－［３－［１［（キナゾリン－４－イル）アミノ］エチル］ピラジン－２－イル］チアゾール－５－カルボニトリル誘導体及び類似化合物 |
| JP2025520650A (ja) | 2022-06-21 | 2025-07-03 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物的に活性な縮合二環式芳香族複素環式化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5444062A (en) | 1990-11-06 | 1995-08-22 | Pfizer Inc. | Quinazolines derivatives for enhancing antitumor activity |
| EP1187633A4 (en) | 1999-04-08 | 2005-05-11 | Arch Dev Corp | USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY |
| AU2001288432A1 (en) * | 2000-09-01 | 2002-03-22 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| US7291733B2 (en) * | 2003-10-10 | 2007-11-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted tricyclic heterocycles and their uses |
| CN101230045B (zh) * | 2008-02-14 | 2013-04-10 | 沈阳药科大学 | 芳环并三嗪类衍生物及其应用 |
| MX2012010557A (es) * | 2010-03-16 | 2012-10-05 | Merck Patent Gmbh | Morfolinilquinazolinas. |
-
2011
- 2011-11-18 DE DE102011118830A patent/DE102011118830A1/de not_active Withdrawn
-
2012
- 2012-10-30 EP EP12783121.2A patent/EP2780332B1/de active Active
- 2012-10-30 AU AU2012339196A patent/AU2012339196B2/en not_active Ceased
- 2012-10-30 DK DK12783121.2T patent/DK2780332T3/en active
- 2012-10-30 CA CA2856103A patent/CA2856103C/en active Active
- 2012-10-30 WO PCT/EP2012/004542 patent/WO2013072015A1/de not_active Ceased
- 2012-10-30 PL PL12783121T patent/PL2780332T3/pl unknown
- 2012-10-30 SG SG11201402206YA patent/SG11201402206YA/en unknown
- 2012-10-30 KR KR1020147016518A patent/KR20140097391A/ko not_active Withdrawn
- 2012-10-30 US US14/351,773 patent/US9187469B2/en active Active
- 2012-10-30 EA EA201400595A patent/EA201400595A1/ru unknown
- 2012-10-30 CN CN201280056504.4A patent/CN103930408B/zh not_active Expired - Fee Related
- 2012-10-30 HU HUE12783121A patent/HUE027577T2/en unknown
- 2012-10-30 SI SI201230559A patent/SI2780332T1/sl unknown
- 2012-10-30 IN IN1287KON2014 patent/IN2014KN01287A/en unknown
- 2012-10-30 HR HRP20160495TT patent/HRP20160495T1/hr unknown
- 2012-10-30 MX MX2014005838A patent/MX2014005838A/es not_active Application Discontinuation
- 2012-10-30 ES ES12783121.2T patent/ES2572605T3/es active Active
- 2012-10-30 HK HK15100269.7A patent/HK1199875A1/xx unknown
- 2012-10-30 JP JP2014541555A patent/JP6096792B2/ja not_active Expired - Fee Related
- 2012-10-30 BR BR112014011805A patent/BR112014011805A2/pt not_active Application Discontinuation
- 2012-10-30 RS RS20160351A patent/RS54768B1/sr unknown
-
2014
- 2014-05-12 IL IL232577A patent/IL232577A/en active IP Right Grant
- 2014-06-17 ZA ZA2014/04438A patent/ZA201404438B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012339196A1 (en) | 2014-07-03 |
| CA2856103A1 (en) | 2013-05-23 |
| EP2780332A1 (de) | 2014-09-24 |
| BR112014011805A2 (pt) | 2017-05-16 |
| KR20140097391A (ko) | 2014-08-06 |
| AU2012339196B2 (en) | 2017-04-27 |
| EP2780332B1 (de) | 2016-02-24 |
| DK2780332T3 (en) | 2016-05-30 |
| SG11201402206YA (en) | 2014-11-27 |
| JP2015502926A (ja) | 2015-01-29 |
| ZA201404438B (en) | 2015-12-23 |
| HRP20160495T1 (hr) | 2016-06-03 |
| JP6096792B2 (ja) | 2017-03-15 |
| CN103930408A (zh) | 2014-07-16 |
| WO2013072015A1 (de) | 2013-05-23 |
| IL232577A (en) | 2017-05-29 |
| CN103930408B (zh) | 2016-09-07 |
| IN2014KN01287A (enExample) | 2015-10-16 |
| RS54768B1 (sr) | 2016-10-31 |
| HUE027577T2 (en) | 2016-10-28 |
| DE102011118830A1 (de) | 2013-05-23 |
| HK1199875A1 (en) | 2015-07-24 |
| IL232577A0 (en) | 2014-06-30 |
| EA201400595A1 (ru) | 2014-11-28 |
| CA2856103C (en) | 2020-08-25 |
| ES2572605T3 (es) | 2016-06-01 |
| US9187469B2 (en) | 2015-11-17 |
| US20140275072A1 (en) | 2014-09-18 |
| PL2780332T3 (pl) | 2016-07-29 |
| SI2780332T1 (sl) | 2016-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014005838A (es) | Morfolinilbenzotriazinas para el uso en la terapia de cancer. | |
| MX2013002259A (es) | Imidazolonilquinolinas [4, 5-c] como inhibidores de proteina cinasa dependiente de adn (adn-pk). | |
| EA201201289A1 (ru) | Морфолинилхиназолины | |
| CY1122611T1 (el) | Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης | |
| EA201300073A1 (ru) | Пиразолохинолины | |
| NZ754827A (en) | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | |
| NZ604480A (en) | Morpholino pyrimidines and their use in therapy | |
| MD20160016A2 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| PH12015501058A1 (en) | Pyrimidine-2,4-diamine derivatives for treatment of cancer | |
| CY1118771T1 (el) | Μακροκυκλικα παραγωγα για την αγωγη υπερπλαστικων παθησεων | |
| EA201490472A1 (ru) | Комбинированная терапия рака hsp90-ингибитором и антиметаболитом | |
| EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
| EA201490891A1 (ru) | Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ | |
| CY1116231T1 (el) | ΑΛΑΤΑ ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ 2,3-ΔIYΔPOΪMIΔAZO[l,2-C] ΚΙΝΑΖΟΛΙΝΗΣ | |
| PH12012500497A1 (en) | Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs | |
| PH12021552233A1 (en) | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kd RELATED DISORDERS | |
| MX2016001011A (es) | Derivados de quinazolin-4-ona sustituida. | |
| ZA201607488B (en) | Compounds for treating brain cancer | |
| MX2014003376A (es) | Derivados de acido benzoico como inhibidores eif4e. | |
| NZ700612A (en) | Methods and compositions for treating ewings sarcoma family of tumors | |
| MX2014008864A (es) | Derivados de triazolo[4,5-d]pirimidina. | |
| PH12014502547A1 (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| EA201492104A1 (ru) | Ингибитор jak1/2 | |
| MX365192B (es) | Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |